Last reviewed · How we verify
Itolizumab [Bmab 600] — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Itolizumab [Bmab 600] (Itolizumab [Bmab 600]) — Equillium.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Itolizumab [Bmab 600] TARGET | Itolizumab [Bmab 600] | Equillium | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Itolizumab [Bmab 600] CI watch — RSS
- Itolizumab [Bmab 600] CI watch — Atom
- Itolizumab [Bmab 600] CI watch — JSON
- Itolizumab [Bmab 600] alone — RSS
Cite this brief
Drug Landscape (2026). Itolizumab [Bmab 600] — Competitive Intelligence Brief. https://druglandscape.com/ci/itolizumab-bmab-600. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab